Cambridge Investment Research Advisors
MIST icon

Cambridge Investment Research Advisors’s Milestone Pharmaceuticals MIST Stock Holding History

Cambridge Investment Research Advisors’s Portfolio MIST Stock Details MIST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18K Sell
13,480
-46,140
-77% -$73.8K ﹤0.01% 4018
2026
Q1 		$71K Buy
59,620
+12,480
+26% +$21.9K ﹤0.01% 3823
2025
Q4 		$95K Buy
47,140
+34,442
+271% +$74.2K ﹤0.01% 3706
2025
Q3 		$25K Buy
+12,698
New +$22.3K ﹤0.01% 3685

Other funds holding MIST

PCM
Pavaki Capital Management Pueblo, Colorado $287M AUM
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Simplify Asset Management
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

Cambridge Investment Research Advisors's MIST Position: Q2 2026 in Review

Cambridge Investment Research Advisors reduced its Milestone Pharmaceuticals (MIST) stake by 77% in Q2 2026, selling an estimated $73.8K and leaving 13,480 shares worth $18K. The position accounts for ﹤0.01% of the portfolio, ranked #4018.

Cambridge Investment Research Advisors first reported a position in MIST in Q3 2025 and has held it in 4 quarters since. The position peaked at $95K in Q4 2025. 78 funds tracked by Wall St. Rank hold MIST as of Q2 2026.

  • Cambridge Investment Research Advisors held 13,480 shares of Milestone Pharmaceuticals worth $18K as of Q2 2026.
  • Cambridge Investment Research Advisors sold 46,140 Milestone Pharmaceuticals shares in Q2 2026, an estimated $73.8K.
  • Milestone Pharmaceuticals made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #4018 holding.
  • Cambridge Investment Research Advisors first reported a position in Milestone Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Cambridge Investment Research Advisors's Milestone Pharmaceuticals position peaked at $95K in Q4 2025.
  • 78 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.